Opportunity Information: Apply for PAR 19 071
This funding opportunity, titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)" (PAR-19-071), is a National Institutes of Health (NIH) discretionary grant program in the health research area (CFDA 93.866). It uses the R21 mechanism, which is generally meant to support early-stage, exploratory, and developmental research. The core goal is to help move promising research tools and approaches forward by generating the additional preliminary data needed to validate them, refine them, and make them usable by a wider set of researchers working on Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD).
The emphasis of the announcement is not on running clinical trials, but on building and strengthening the foundational research "building blocks" that can accelerate progress across the field. The FOA explicitly invites applications that propose new or improved tests, animal models, techniques, and similar research-enabling resources relevant to AD/ADRD. In practical terms, this could include developing or optimizing experimental assays, creating or characterizing model systems, improving methodological approaches, or producing other broadly applicable tools that address current needs in dementia research. A key point is that the proposed resource or approach should be at a stage where it is promising but still needs more preliminary evidence and broader exposure to establish it for more general use.
Another defining feature is that the most important research topics under this opportunity are not fixed permanently within the announcement itself. Instead, the NIH plans to announce priority topics through a series of Notices published after the FOA. This means applicants are expected to pay attention to those subsequent NIH Notices to understand which specific "current topics" are being highlighted at a given time and to align proposals accordingly.
Eligibility is broad and is designed to include a wide range of organizations capable of contributing to AD/ADRD research infrastructure and methods development. Eligible applicants include various levels of U.S. government (state, county, city/township, and special district governments), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, and Native American tribal organizations that are not federally recognized. The opportunity is also open to nonprofits with and without 501(c)(3) status (as long as they are not institutions of higher education), for-profit organizations other than small businesses, and small businesses. In addition, the FOA notes other eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations). The inclusion of these categories signals an intent to draw from a diverse set of institutions and communities to strengthen the research ecosystem around dementia.
From the funding details provided, the award ceiling is listed as $200,000, indicating the maximum amount expected per award under the terms shown in the source data. The original closing date in the record is 2021-11-12, and the FOA record shows a creation date of 2018-11-16. While the record includes a field for expected awards, it is not populated in the provided data, so the number of awards is not specified here. Overall, the opportunity is best understood as a targeted R21 program aimed at accelerating AD/ADRD progress by funding the development and validation of widely useful research tools and methods, with the exact topical priorities evolving over time via NIH-issued Notices.Apply for PAR 19 071
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2018-11-16.
- Applicants must submit their applications by 2021-11-12. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed) (PAR-19-071)
1) What is this funding opportunity?
This is a National Institutes of Health (NIH) discretionary grant funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)" (PAR-19-071). It is in the health research area and is associated with CFDA 93.866.
2) What is the main purpose of this FOA?
The core goal is to accelerate progress in Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) by supporting the development, validation, refinement, and broader usability of promising research tools, approaches, and other foundational resources. The intent is to generate the preliminary data needed to move a tool or method from "promising" to "ready for wider use" by the research community.
3) What grant mechanism does it use and what does that imply?
This FOA uses the NIH R21 mechanism, which is generally designed for early-stage, exploratory, and developmental research. In practical terms, the program is oriented toward building out and strengthening research-enabling "building blocks" rather than supporting large, mature programs.
4) Are clinical trials allowed under this opportunity?
No. The funding opportunity is explicitly labeled "Clinical Trial Not Allowed," and the emphasis is not on running clinical trials.
5) If clinical trials are not allowed, what kinds of projects are encouraged?
The FOA invites applications focused on creating, improving, or strengthening research-enabling resources for AD/ADRD. Examples described in the opportunity include new or improved tests, animal models, techniques, experimental assays, model systems, and methodological approaches, as well as other broadly applicable tools that address current needs in dementia research.
6) What does NIH mean by "foundational research building blocks" in this context?
Based on the description provided, "building blocks" refers to practical resources and methods that can be reused by many researchers to speed up progress across the field. This includes tools and approaches that require additional preliminary evidence, validation, refinement, or characterization so they can become usable by a wider set of AD/ADRD researchers.
7) Does the FOA focus on fixed topic areas?
No. A defining feature is that the most important research topics are not permanently fixed within the announcement text. NIH plans to publish priority topics through a series of Notices released after the FOA.
8) How do applicants know what the current priority topics are?
Applicants are expected to monitor subsequent NIH Notices associated with the FOA. Those Notices are where NIH will highlight which specific "current topics" are being prioritized at a given time, and applicants should align proposals accordingly.
9) What stage of tool or approach is this FOA trying to fund?
The opportunity is aimed at resources that are promising but still need additional preliminary data and broader exposure to establish them for more general use. The emphasis is on generating evidence to validate and refine the tool or method so it can be adopted more widely.
10) Who is eligible to apply?
Eligibility is broad and includes many organization types capable of contributing to AD/ADRD research infrastructure and methods development. Eligible applicants include U.S. state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and Native American tribal organizations that are not federally recognized.
11) Can nonprofits apply?
Yes. The FOA is open to nonprofits with and without 501(c)(3) status, as long as they are not institutions of higher education.
12) Can for-profit organizations apply?
Yes. Eligible applicants include for-profit organizations other than small businesses, and small businesses are also listed as eligible.
13) Are small businesses eligible?
Yes. Small businesses are explicitly included among the eligible applicant types.
14) Are minority-serving institutions specifically included?
Yes. The FOA notes eligibility for categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and other related categories.
15) Are faith-based or community-based organizations eligible?
Yes. Faith-based and community-based organizations are included in the list of eligible applicant categories.
16) Can federal agencies apply?
Yes. Eligible federal agencies are listed among the eligible applicant categories.
17) Are applicants from U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are included in the eligible applicant categories.
18) Are foreign (non-U.S.) organizations eligible to apply?
Yes. The FOA indicates that non-U.S. entities (foreign organizations) are eligible.
19) What is the maximum award amount mentioned in the provided record?
The award ceiling listed in the provided information is $200,000, which indicates the maximum amount expected per award under the terms shown in the source data.
20) Does the provided information specify how many awards NIH expects to make?
No. The field for expected awards is not populated in the provided data, so the number of awards is not specified here.
21) What are the key dates shown in the provided record?
The record shows a creation date of 2018-11-16 and an original closing date of 2021-11-12.
22) What should a strong application concept emphasize based on the FOA description?
Based on the provided description, a strong concept would emphasize development and validation of broadly useful AD/ADRD research tools or methods, including generation of additional preliminary data needed to refine the resource and demonstrate its wider usefulness. It should also align with the "current topics" NIH identifies through subsequent Notices.
23) Is this opportunity primarily intended to fund direct patient-focused intervention studies?
No. The emphasis described is on research-enabling resources and methods development, and clinical trials are not allowed under this FOA.
24) What kinds of outputs or deliverables does the FOA appear to be aiming for?
The FOA is aimed at practical, reusable research resources such as improved tests, assays, animal models, techniques, and methodological approaches, along with the supporting preliminary data and validation needed to make those outputs usable by a wider group of AD/ADRD researchers.
Browse more opportunities from the same category: Health
Next opportunity: Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
Previous opportunity: Research Project Grant (Parent R01 Clinical Trial Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 19 071
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 19 071) also looked into and applied for these:
| Funding Opportunity |
|---|
| Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 18 057 Funding Number: RFA AI 18 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R21 Clinical Trial Optional) Apply for RFA MH 19 411 Funding Number: RFA MH 19 411 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R34 Clinical Trial Required) Apply for RFA MH 19 410 Funding Number: RFA MH 19 410 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R01 Clinical Trial Optional) Apply for RFA MH 19 412 Funding Number: RFA MH 19 412 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44 Clinical Trial Not Allowed) Apply for PA 19 076 Funding Number: PA 19 076 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Development of Rapid Fungal Diagnostics (R21 Clinical Trial Not Allowed) Apply for PA 19 081 Funding Number: PA 19 081 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed) Apply for PAR 19 079 Funding Number: PAR 19 079 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R01 Clinical Trial Not Allowed) Apply for PA 19 082 Funding Number: PA 19 082 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R21 Clinical Trial Not Allowed) Apply for PA 19 083 Funding Number: PA 19 083 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42 Clinical Trial Not Allowed) Apply for PA 19 075 Funding Number: PA 19 075 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed) Apply for PA 19 077 Funding Number: PA 19 077 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Development of Rapid Fungal Diagnostics (R01 Clinical Trial Not Allowed) Apply for PA 19 080 Funding Number: PA 19 080 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed) Apply for PAR 19 078 Funding Number: PAR 19 078 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol-HIV/AIDS Program Project (P01 Clinical Trial Optional) Apply for RFA AA 19 002 Funding Number: RFA AA 19 002 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Emotion Regulation, Aging and Mental Disorder (R01 Clinical Trial Not Allowed) Apply for PA 19 094 Funding Number: PA 19 094 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| A Practice-Based Research Network to Transform Mental Health Care: Science, Service Delivery and Sustainability (U19 Clinical Trial Required) Apply for RFA MH 19 225 Funding Number: RFA MH 19 225 Agency: National Institutes of Health Category: Health Funding Amount: $130,000 |
| Genetic Engineering Technologies for HIV Cure Research (U19 Clinical Trial Optional) Apply for RFA AI 18 058 Funding Number: RFA AI 18 058 Agency: National Institutes of Health Category: Health Funding Amount: $175,000 |
| Exploring Molecular Links Between Dietary Interventions and Circadian Rhythm (R01 Clinical Trial Not Allowed) Apply for RFA AG 19 029 Funding Number: RFA AG 19 029 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-infection (R01 Clinical Trial Not Allowed) Apply for PAS 19 097 Funding Number: PAS 19 097 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Emotion Regulation, Aging and Mental Disorder (R21 Clinical Trial Not Allowed) Apply for PA 19 095 Funding Number: PA 19 095 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 19 071", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.